GlassScriptPhysician profile
Laura C Clark
NPI 1447360458
$1,624.44
in general payments reported to CMS, 2019-2025
28 companies · $389 in 2025
The $389 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $141 · 2021: $151 · 2022: $213 · 2023: $190 · 2024: $358 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $207.48 | 2019-2025 | |
| Glaxosmithkline, LLC. | $172.28 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $138.99 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $137.90 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $125.73 | 2019-2024 | |
| Alk-Abello, INC | $108.31 | 2023-2025 | Ragwitek, Grastek, Odactra |
| Tris Pharma INC | $89.15 | 2020-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $72.13 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $54.75 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $54.22 | 2019-2020 | |
| Kaleo, INC. | $49.81 | 2019-2023 | Auvi-Q |
| Adlon Therapeutics L.P. | $49.40 | 2021 | |
| Biogen, INC. | $48.40 | 2024 | Spinraza |
| Sanofi-Aventis U.S. LLC | $45.97 | 2025 | |
| Allergan, INC. | $37.33 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $32.36 | 2022-2024 | |
| Corium, LLC | $29.46 | 2022 | |
| Verrica Pharmaceuticals INC. | $21.29 | 2024 | Ycanth |
| Krystal Biotech INC | $20.20 | 2025 | Vyjuvek |
| Biomarin Pharmaceutical INC. | $17.75 | 2021 | |
| Fidia Pharma USA INC. | $17.64 | 2024 | Triluron, Hymovis, Hyalgan |
| Biomerieux INC | $15.46 | 2025 | Biofire Spotfire Control Station |
| Cognoa, INC. | $14.67 | 2022 | |
| Aimmune Therapeutics, INC. | $14.54 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2024 | Flumist Quadrivalent |
| Boston Scientific Corporation | $12.34 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.